Apoptose
Os inibidores da apoptose são compostos que previnem ou retardam o processo de morte celular programada, conhecido como apoptose. Esses inibidores são vitais no estudo dos mecanismos de sobrevivência celular e são usados para investigar doenças onde a apoptose é desregulada, como câncer, distúrbios neurodegenerativos e doenças autoimunes. Ao modular a apoptose, esses inibidores podem ajudar no desenvolvimento de terapias destinadas a controlar a morte celular. Na CymitQuimica, oferecemos uma ampla seleção de inibidores da apoptose de alta qualidade para apoiar sua pesquisa em biologia celular, oncologia e áreas relacionadas.
Subcategorias de "Apoptose"
- ASK(6 produtos)
- BCL(11 produtos)
- Caspase(125 produtos)
- FOXO1(3 produtos)
- IAP(66 produtos)
- Mdm2(12 produtos)
- PD-1/PD-L1(125 produtos)
- PDK(9 produtos)
- PERK(25 produtos)
- Serina/treonina quinase(15 produtos)
- Survivina(13 produtos)
- TNF(92 produtos)
- c-RET(51 produtos)
- p53(62 produtos)
Exibir 6 mais subcategorias
Foram encontrados 5598 produtos de "Apoptose"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR/VEGFR2-IN-3
CAS:<p>EGFR/VEGFR2-IN-3 (compound 9) is an effective inhibitor of EGFR and VEGFR-2, demonstrating IC50 values of 0.129 µM for EGFR, 0.142 µM for VEGFR-2, and 3.428 µM for COX-2. This compound exhibits cytotoxic properties and induces cell apoptosis (apoptosis) as well as cell cycle arrest at the G2/M phase.</p>Fórmula:C24H20ClN5O2S2Cor e Forma:SolidPeso molecular:510.03MLKL-IN-6
<p>MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor that specifically targets the Mixed Lineage Kinase domain-like (MLKL) protein.</p>Fórmula:C20H18N4O5Pureza:98%Cor e Forma:SolidPeso molecular:394.38FKBP12 PROTAC dTAG-13
CAS:<p>FKBP12 PROTAC dTAG-13 is a PROTAC and selective degrader for target validation by splicing FKBP12 F36V with CRBN and thereby degrading FKBP12 F36V.</p>Fórmula:C57H68N4O15Pureza:97.31%Cor e Forma:SolidPeso molecular:1049.17FLT3-ITD-IN-3
CAS:<p>FLT3-ITD-IN-3 (13v) is an orally active inhibitor of FLT3-ITD (internal tandem duplication of FLT3), which works by blocking FLT3 signaling. This inhibition leads to cell cycle arrest in the G0/G1 phase and induces apoptosis. The compound is currently employed in studies related to acute myeloid leukemia (AML).</p>Fórmula:C27H21ClF2N6O5Cor e Forma:SolidPeso molecular:582.943Anticancer agent 14
<p>Anticancer agent 14: a potent breast cancer inhibitor; induces cell death, disrupts mito. membrane potential (IC50: 0.20-0.65 μM).</p>Fórmula:C29H34N2O3Cor e Forma:SolidPeso molecular:458.59Multi-kinase-IN-1
CAS:<p>Multi-kinase-IN-1, a powerful kinase inhibitor, exhibits antitumor properties by inducing cell apoptosis.</p>Fórmula:C35H36F2N6O6SCor e Forma:SolidPeso molecular:706.76Sinulatumolin E
CAS:<p>Sinulatumolin E, a terpenoid, inhibits TNF-α (IC 50: 3.6 μM); has anti-inflammatory properties.</p>Fórmula:C15H22O2Cor e Forma:SolidPeso molecular:234.33GLS1 Inhibitor-6
<p>GLS1 Inhibitor-6: IC50=68nM, 220x more selective for GLS2, has anti-tumor and pro-apoptosis effects.</p>Fórmula:C37H52N6O3SCor e Forma:SolidPeso molecular:660.91ZLHQ-5f
<p>ZLHQ-5f inhibits CDK2/Topo I, with IC50 of 0.145μM for CDK2/CycA2, and promotes apoptosis by arresting HCT116 cells in S phase.</p>Fórmula:C28H25N5O2Cor e Forma:SolidPeso molecular:463.53MDK-3345
CAS:<p>MDK-3345 is a reversible covalent inhibitor for Mcl-1.</p>Fórmula:C36H34BN3O7Pureza:98%Cor e Forma:SolidPeso molecular:631.48HSP90-IN-10
<p>HSP90-IN-10 is a potent HSP90 inhibitor, targeting HCC1954 cells (IC50: 6 μM) and inducing apoptosis, sparing normal cells.</p>Fórmula:C30H26FN3O6Cor e Forma:SolidPeso molecular:543.54WEHI-9625
CAS:<p>WEHI-9625 is a tricyclic sulfone small molecule apoptosis inhibitor (EC50: 69 nM).</p>Fórmula:C34H27NO5S2Pureza:98%Cor e Forma:SolidPeso molecular:593.71RET-IN-10
CAS:<p>RET-IN-10: Potent RET inhibitor, may treat congenital megacolon and tumors (Patent WO2021135938A1, compound 18).</p>Fórmula:C29H28N8OSCor e Forma:SolidPeso molecular:536.65Lometrexol hydrate
CAS:<p>Lometrexol hydrate, an antipurine antifolate, inhibits GARFT and purine synthesis, leading to cancer cell apoptosis without causing DNA breaks.</p>Fórmula:C21H27N5O7Cor e Forma:SolidPeso molecular:461.475TOPOI/PARP-1-IN-1
CAS:<p>Compound B6, also known as TOPOI/PARP-1-IN-1, is a dual inhibitor targeting TOPOI and PARP, exhibiting low cytotoxicity and oral activity with a PARP1 IC 50 of 0.09 μM. This compound effectively inhibits cancer cell proliferation and migration, induces cell cycle arrest at the G0/G1 phase, and triggers apoptosis. In murine models, TOPOI/PARP-1-IN-1 demonstrated a tumor growth inhibition rate (TGI) of 75.4% [1].</p>Fórmula:C36H38Br2N4O2Cor e Forma:SolidPeso molecular:718.523-AP-Me
CAS:<p>3-AP-Me is the dimethyl derivative of the ribonucleotide reductase inhibitor 3-AP (SML0568). It activates the endoplasmic reticulum (ER) stress pathway by promoting eIF2α phosphorylation and upregulating gene expression of transcription factors ATF4 and ATF6, thereby inducing apoptosis. Additionally, 3-AP-Me activates cellular stress kinases c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase, leading to the upregulation of spliced mRNA variant XBP1. It is applicable in cancer research.</p>Fórmula:C9H13N5SCor e Forma:SolidPeso molecular:223.298Casein kinase 1δ-IN-29
CAS:<p>Casein kinase1δ-IN-29 (Compound 18) is an inhibitor that targets p38α and casein kinase 1 (CK1), exhibiting inhibitory effects on p38α, CK1δ, and CK1ε with IC50 values of 0.041 µM, 0.005 µM, and 0.447 µM, respectively. This compound causes cell cycle arrest at the subG1 phase and induces apoptosis in AC1-M88 cells.</p>Fórmula:C26H23FN4O4SCor e Forma:SolidPeso molecular:506.549DDO-8958
CAS:<p>DDO-8958 is an orally active and selective BET BD1 inhibitor, exhibiting a KD of 5.6 nM for BRD4 BD1. It shows low nanomolar inhibitory activity across all BET BD1 bromodomains except for BRDT BD1. DDO-8958 inhibits tumor cell proliferation and migration, induces apoptosis and cell cycle arrest, and demonstrates antitumor activity.</p>Fórmula:C22H22FN5O2Cor e Forma:SolidPeso molecular:407.441Elocalcitol
CAS:<p>Elocalcitol is a calcitriol analog for inhibition of prostate cell growth.</p>Fórmula:C29H43FO2Cor e Forma:SolidPeso molecular:442.65TP-030-1
CAS:<p>TP-030-1, RIPK1 inhibitor: K(i) hRIPK1 at 3.9nM, IC50 mRIPK1 at 4.2μM; targets inflammation, neurodegeneration research.</p>Fórmula:C23H22N4O3Cor e Forma:SolidPeso molecular:402.45GRP78-IN-1
<p>GRP78-IN-1 binds to GRP78 protein, inhibits cell growth, and triggers apoptosis in breast cancer; has -8.07 kcal/mol binding energy.</p>Fórmula:C21H23FO3Cor e Forma:SolidPeso molecular:342.4GL0388
<p>GL0388, a Bax activator, induces apoptosis, hinders breast cancer growth, and has IC50 of 0.299-1.57 μM.</p>Fórmula:C21H17FN2OCor e Forma:SolidPeso molecular:332.37TrxR/EGFR-IN-1
CAS:<p>TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor with activity against both gefitinib-sensitive and -resistant lung cancer, effectively suppressing tumor proliferation and promoting apoptosis. It enhances GPX4 degradation through autophagosome-lysosome and proteasome pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it applicable for studies on gefitinib-resistant lung cancer.</p>Fórmula:C24H24AuClFN6O2PCor e Forma:SolidPeso molecular:710.878c-Met/HDAC-IN-2
CAS:<p>Potent dual c-Met/HDAC inhibitor, IC50: HDAC1 5.4 nM, c-Met 18.49 nM; anti-cancer, induces apoptosis, G2/M arrest in HCT-116.</p>Fórmula:C34H33N5O7Cor e Forma:SolidPeso molecular:623.66HDAC6/HSP90-IN-2
<p>HDAC6/HSP90-IN-2, a cancer research chemical, inhibits HDAC6 & Hsp90 with IC50s of 105.7 & 61 nM.</p>Fórmula:C19H22N2O5Cor e Forma:SolidPeso molecular:358.39AKN-028 acetate
<p>AKN-028 acetate: an oral TK inhibitor for AML research, targets FLT3 with IC50 of 6 nM, inhibits autophosphorylation, and induces apoptosis.</p>Fórmula:C19H18N6O2Cor e Forma:SolidPeso molecular:362.39Tubulin polymerization-IN-6
<p>Compound 5f, a potent tubulin polymerization inhibitor (IC50 = 1.09 μM), blocks cell migration, tube formation, and has anti-angiogenic effects.</p>Fórmula:C19H21NO7Cor e Forma:SolidPeso molecular:375.37AKT-IN-3
CAS:<p>AKT-IN-3: potent oral Akt inhibitor with low hERG blockage. IC50: 1.4-1.7 nM for Akt1-3. Inhibits AGC kinases like PKA, PKC.</p>Fórmula:C23H23Cl2F2N5O3Pureza:98%Cor e Forma:SolidPeso molecular:526.36MY-875
<p>MY-875 inhibits microtubule formation, binds like colchicine (IC50: 0.92 μM), activates Hippo pathway, and induces apoptosis with anticancer properties.</p>Fórmula:C21H25NO6Cor e Forma:SolidPeso molecular:387.43Glyphosate isopropylammonium
CAS:<p>Glyphosate isopropylammonium is a broad-spectrum, non-selective systemic biocide derived from the amino acid glycine. It inhibits the enzyme activity of 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS) in the shikimate pathway, blocking the synthesis of aromatic amino acids tyrosine, phenylalanine, and tryptophan. Additionally, Glyphosate isopropylammonium induces oxidative stress, neuroinflammation, and mitochondrial dysfunction, leading to neuronal death through autophagy, necrosis, or apoptosis, resulting in behavioral and motor disturbances.</p>Fórmula:C6H17N2O5PPeso molecular:228.18ZLWT-37
<p>ZLWT-37: Oral CDK inhibitor, CDK9 IC50=0.002 µM, CDK2 IC50=0.054 µM; halts HCT116 cells at G2/M, induces apoptosis.</p>Fórmula:C26H30ClN5OCor e Forma:SolidPeso molecular:464Anticancer agent 69
<p>Anticancer agent 69 targets PC3 cells (IC50=26 nM), raises ROS, lowers EGFR, and induces apoptosis.</p>Fórmula:C19H26N8SCor e Forma:SolidPeso molecular:398.53JAK2/FLT3-IN-1 TFA
<p>JAK2/FLT3-IN-1 (TFA), an oral JAK2/FLT3 inhibitor, shows anticancer properties; IC50: JAK2 (0.7 nM), FLT3 (4 nM), JAK1 (26 nM), JAK3 (39 nM).</p>Fórmula:C27H35F4N7O3Cor e Forma:SolidPeso molecular:581.61PD-1-IN-17 TFA
<p>PD-1-IN-17 TFA is a potent PD-1 inhibitor, blocking 92% of splenocyte growth at 100 nM.</p>Fórmula:C15H23F3N6O9Cor e Forma:SolidPeso molecular:488.37VEGFR-2-IN-13
<p>VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor (IC50: 3.4 nM). vEGFR-2-IN-13 arrests the HepG2 cell cycle in G2/M phase and induces apoptosis.</p>Fórmula:C24H18N6O2SCor e Forma:SolidPeso molecular:454.5T0080
CAS:<p>T0080 is an FPR-1 antagonist. It reduces apoptosis (Apoptosis) and inhibits the production of reactive oxygen species (ROS) and pro-inflammatory cytokines (TNF-α and IL-1β) in plaque macrophages within ApoE−/− mouse models, thereby slowing the progression of atherosclerosis.</p>Fórmula:C24H22F3N3O3Cor e Forma:SolidPeso molecular:457.45Thalidomide-Piperazine-PEG1-NH2
CAS:<p>Thalidomide-Piperazine-PEG1-NH2 is a synthetic E3 ligase ligand-linker conjugate, featuring a cereblon ligand based on Thalidomide and a single linker.</p>Fórmula:C21H27N5O5Peso molecular:429.47Aeroplysinin 1
CAS:<p>Aeroplysinin I is an antibacterial compound from the sponge. It has cytotoxic activity against colon cancer cells by promoting β-catenin degradation.</p>Fórmula:C9H9Br2NO3Cor e Forma:SolidPeso molecular:338.98Enpp-1-IN-25
CAS:<p>Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and exhibits low oral bioavailability. By inhibiting cGAMP degradation, it effectively activates the intracellular STING pathway. Enpp-1-IN-25 can enhance immune cell infiltration and type I interferon response in the tumor microenvironment, thereby increasing the antitumor efficacy of anti-PD-L1 antibodies. It is applicable for research in cancer immunotherapy.</p>Fórmula:C15H21N5O4SCor e Forma:SolidPeso molecular:367.423CIL-102
CAS:<p>CIL-102 is an apoptosis inducer that functions as an MMP-2/MMP-9 inhibitor, effectively reducing both the protein expression and mRNA levels of MMP-2/MMP-9. CIL-102 also demonstrates anticancer activity.</p>Fórmula:C19H14N2O2Cor e Forma:SolidPeso molecular:302.327HC-7366
CAS:<p>HC-7366 (GCN2 modulator-1) is an orally active GCN2 kinase activator with antitumor activity, inducing tumor growth inhibition.</p>Fórmula:C20H15ClF2N6O4SPureza:99.84%Cor e Forma:SolidPeso molecular:508.89CCT369260
CAS:<p>CCT369260 (compound 1), an orally active inhibitor targeting B-cell lymphoma 6 (BCL6), demonstrates anti-tumor efficacy with an IC50 value of 520 nM [1].</p>Fórmula:C24H31ClF2N6O2Cor e Forma:SolidPeso molecular:508.99hCAIX/XII-IN-5
<p>Coumarin 9a: Selective inhibitor of hCA IX/XII (Ki 93.3/85.7 nM), blocks cancer cell growth, and induces apoptosis.</p>Fórmula:C18H13NO3Cor e Forma:SolidPeso molecular:291.3PD-1/PD-L1-IN-15
<p>PD-1/PD-L1-IN-15 is a potent inhibitor of PD-1/PD-L1 (IC50: 60.1 nM) and has shown investigational potential for tumor immunotherapy.</p>Fórmula:C32H30N4O3Cor e Forma:SolidPeso molecular:518.61MJC13
CAS:<p>MJC13 is an FKBP52-targeting agent with antitumor activity, suitable for prostate cancer research.</p>Fórmula:C13H15Cl2NOCor e Forma:SolidPeso molecular:272.17NVP-CGM097 sulfate
CAS:<p>NVP-CGM097 sulfate is a potent and selective inhibitor of MDM2 (hMDM2, IC50 of 1.7±0.1 nM).</p>Fórmula:C38H49ClN4O8SPureza:98%Cor e Forma:SolidPeso molecular:757.34PI4KIII β inhibitor 4
CAS:<p>PI4KIII beta inhibitor 4 (Compound 16) is a selective inhibitor of PI4KIIIβ with an IC50 of 0.005 μM. By inhibiting the PI3K/AKT pathway, PI4KIII beta inhibitor 4 induces apoptosis, causes cell cycle arrest, and triggers autophagy in tumor cells. This compound is applicable for tumor research.</p>Fórmula:C24H36N4O6S2Cor e Forma:SolidPeso molecular:540.696Antitumor agent-43
<p>Antitumor agent-43 (Compound 4B) is a potent antitumor agent that induces cell cycle arrest at G2/M phase.</p>Fórmula:C16H8N2O3Cor e Forma:SolidPeso molecular:276.25RIPK1-IN-28
CAS:<p>RIPK1-IN-28 (compound 13) is an orally active inhibitor of RIPK1. It exhibits inhibitory effects on human I2.1 and Hepa1-6 cells, with IC50 values of 0.4 and 1.2 nM, respectively.</p>Fórmula:C27H24N4O4Cor e Forma:SolidPeso molecular:468.504SIRT-IN-7
CAS:<p>SIRT-IN-7 (Compound 7ba) is a SIRT inhibitor. It effectively suppresses the expression of SIRT1, SIRT2, and SIRT3, leading to increased acetylation and activation of p53. Additionally, SIRT-IN-7 inhibits the proliferation of breast cancer cells and induces apoptosis and autophagy, demonstrating antitumor activity.</p>Fórmula:C24H16BrClN2OSCor e Forma:SolidPeso molecular:495.819Tubulin inhibitor 14
<p>Tubulin inhibitor 14 blocks NQO2 and microtubule formation, disrupts blood vessels, and may target tumors; IC50 of 1.0 μM.</p>Fórmula:C15H9F2NOCor e Forma:SolidPeso molecular:257.23RET-IN-11
<p>RET-IN-11 selectively inhibits RET (IC50: 6.20 nM), promotes apoptosis, and hinders cell proliferation and migration.</p>Fórmula:C27H30FN9OCor e Forma:SolidPeso molecular:515.59Casuarinin
CAS:<p>Casuarinin, an ellagitannin found in pomegranates and certain Casuarina/Stachyurus plants, is a carbonic anhydrase inhibitor and astringent.</p>Fórmula:C41H28O26Cor e Forma:SolidPeso molecular:936.65EGFR-IN-3
<p>EGFR-IN-3 is an EGFR inhibitor with antitumor activity.EGFR-IN-3 inhibits EGFRwt-TK, induces apoptosis (cell death), and can block cells in the G2/M phase.</p>Fórmula:C24H18F4N6O2SPureza:98.1%Cor e Forma:SolidPeso molecular:530.5EGFR/HER2-IN-6
<p>EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.</p>Fórmula:C18H21N5O3SCor e Forma:SolidPeso molecular:387.46Thalidomide-NH-amido-C4-NH2
CAS:<p>Thalidomide-NH-amido-C4-NH2 is a synthetic E3 ligase ligand-linker conjugate composed of a Thalidomide-based cereblon ligand and a linker, which is utilized in the synthesis of PROTAC.</p>Fórmula:C19H23N5O5Peso molecular:401.42Scytonemin
CAS:<p>Scytonemin, a cyanobacterial pigment, inhibits cancer cell growth by decreasing Plk1 activity, especially effective on U266 myeloma cells.</p>Fórmula:C36H20N2O4Cor e Forma:SolidPeso molecular:544.55Z-VA-DL-D-FMK
CAS:Z-VA-DL-D-FMK (Z-VA-DL-D(OH)-FMK) acts as an inhibitor of caspases. It irreversibly binds to caspases, enhancing the sensitivity to TNF-α and stimulating HIV replication in infected T cells ACH-2.Fórmula:C21H28FN3O7Cor e Forma:SolidPeso molecular:453.46SMIP34
CAS:<p>SMIP34 is an inhibitor of PELP1, binding to this target with a dissociation constant (Kd) of 37.4 μM. It demonstrates efficacy in inhibiting the proliferation of cancer cells and tumor progression. Specifically, SMIP34 is effective in breast cancer research, showing activity against wild-type (WT), mutant (MT) estrogen receptor-positive (ER+), and treatment-resistant (TR)-ER+ breast cancers.</p>Fórmula:C25H32ClN5O3Cor e Forma:SolidPeso molecular:486.01FAK-IN-2
<p>FAK-IN-2: potent oral FAK inhibitor, IC50 35 nM, reduces tumor growth, migration, and induces cell death.</p>Fórmula:C28H31ClN8O3Cor e Forma:SolidPeso molecular:563.05Triphen diol
CAS:<p>Triphen diol, a phenol diol, fights pancreatic cancer & cholangiocarcinoma, inducing apoptosis via caspase-dependent & -independent paths.</p>Fórmula:C22H20O4Cor e Forma:SolidPeso molecular:348.39NLRP3-IN-28
CAS:<p>NLRP3-IN-28 (compound N77) serves as a potent inhibitor of NLRP3, effectively blocking Nigericin-induced pyroptosis with an EC50 of 0.07μM. Additionally, it mitigates inflammatory reactions in vivo [1].</p>Fórmula:C12H9F3N2O3SCor e Forma:SolidPeso molecular:318.27Tubulin/NRP1-IN-1
CAS:<p>Tubulin/NRP1-IN-1 (compound TN-2) serves as a dual inhibitor targeting both Tubulin and NRP1, exhibiting IC50 values of 0.71 μM and 0.85 μM, respectively. This compound notably reduces the viability of prostate tumor cell lines and triggers apoptosis [1].</p>Fórmula:C28H37N5O8Cor e Forma:SolidPeso molecular:571.62MD102
CAS:<p>MD102, with an IC50 value of 0.35 μM, is a potent TG2 inhibitor that stabilizes p53 by inhibiting TG2. This results in a decrease in p-AKT and p-mTOR downstream signaling, ultimately inducing tumor cell apoptosis [1].</p>Fórmula:C13H4BrCl2FN2O2Cor e Forma:SolidPeso molecular:389.99NLRP3-IN-78
CAS:<p>NLRP3-IN-78 (compound 21) is an NLRP3 inhibitor with a 46.72% inhibition rate of GSDMD-induced pyroptosis at 5 μM. It binds to the NLRP3 protein and prevents GSDMD-NT oligomerization. Additionally, NLRP3-IN-78 inhibits GSDMD cleavage and upstream NF-κB signaling, demonstrating anti-inflammatory activity.</p>Fórmula:C12H5Cl2N3O4S2Cor e Forma:SolidPeso molecular:390.222RIP3 activator 1
CAS:<p>RIP3 Activator 1 (compound C8) is an effective RIP3 activator that inhibits cell growth and induces necroptotic cell death (necroptosis) and autophagy through the RIP3/p62/Keap1 signaling pathway. Additionally, this compound enhances the expression of p-MLKL and promotes the accumulation of LC3-II and p62 proteins.</p>Fórmula:C26H50N4O3Cor e Forma:SolidPeso molecular:466.7MG28
CAS:<p>MG28 exhibits significant cytotoxic effects, likely stemming from its direct and potent DNA-damaging activity. The compound is utilized in cancer research.</p>Fórmula:C27H25NO3SCor e Forma:SolidPeso molecular:443.56MA242
CAS:<p>MA242 is a nuclear factor of activated T cells 1 (NFAT1) for Pancreatic Cancer Therapy and dual inhibitor of murine double minute 2 (MDM2).</p>Fórmula:C26H21ClF3N3O5SPureza:98%Cor e Forma:SolidPeso molecular:579.98JR5-26B
CAS:<p>JR5-26B is an orally active apoptosis (apoptosis) inducer. It induces cell death via copper-mediated apoptosis and necroptosis (necroptosis). JR5-26B exhibits antiproliferative activity against MIA PaCa-2, PANC-1, PAN02, SU.86.86, and KPC-2 cells, with IC50 values of 0.6, 4.4, 8.0, 1.1, and 3.4 μM, respectively.</p>Fórmula:C19H17FN6OCor e Forma:SolidPeso molecular:364.38VNPP433-3β
CAS:<p>VNPP433-3β acts as a molecular glue degrader, targeting the androgen receptor (AR) and its splice variants (AR-Vs) as well as MAP kinase-interacting serine/threonine protein kinase Mnk1/2. It effectively inhibits the proliferation of cancer cells LNCaP, C4-2B, and CWR22Rv1, with GI50 values of 0.2, 0.3, and 0.31 μM, respectively. Additionally, VNPP433-3β shows favorable pharmacokinetics in CD-1 mice and suppresses tumor growth in the CWR22Rv1 xenograft mouse model.</p>Fórmula:C29H34N4Cor e Forma:SolidPeso molecular:438.61Topoisomerase I/II inhibitor 3
<p>Topoisomerase I/II inhibitor 3 suppresses cell growth and induces apoptosis in liver cancer by blocking PI3K/Akt/mTOR.</p>Fórmula:C24H24N2O4Cor e Forma:SolidPeso molecular:404.46BRD4/CK2-IN-1
CAS:<p>BRD4/CK2-IN-1 is a small-molecule inhibitor targeting BRD4 and CK2, inducing apoptosis and autophagy-related cell death.</p>Fórmula:C29H30ClN5O5Pureza:99.02%Cor e Forma:SolidPeso molecular:564.03Kahweol Acetate
CAS:<p>Kahweol Acetate, a semi-synthetic coffee bean derivative, inhibits osteoclasts, cancer cells, DNA damage, and oxidative stress.</p>Fórmula:C22H28O4Cor e Forma:SolidPeso molecular:356.46Oxamic acid
CAS:<p>Oxamic acid is an inhibitor of LDH-A and exhibits antitumor activity. It demonstrates antiproliferative effects on cancer cells and can induce apoptosis.</p>Fórmula:C2H3NO3Cor e Forma:SolidPeso molecular:89.05(Rac)-Idroxioleic acid sodium
CAS:<p>(Rac)-Idroxioleic acid (2-Hydroxyoleic acid) sodium is a synthetic derivative of oleic acid (OA) that binds to the plasma membrane, altering lipid composition. This compound exhibits antitumor properties.</p>Fórmula:C18H33NaO3Cor e Forma:SolidPeso molecular:320.44Mcl-1 inhibitor 9
CAS:<p>Mcl-1 Inhibitor 9 (Example 2) is a potent inhibitor of myeloid cell leukemia 1 (Mcl-1), demonstrating anti-tumor activity with an IC50 value of 0.21889 nM.</p>Fórmula:C32H39ClN2O5SCor e Forma:SolidPeso molecular:599.18Top/HDAC-IN-3
CAS:<p>Top/HDAC-IN-3 (Compound 31) is a dual inhibitor of Topoisomerase and HDAC with oral activity. It induces DNA damage by elevating reactive oxygen species (ROS) levels, consequently inhibiting the clonal formation and migration of cancer cells, and triggering apoptosis (Apoptosis) and cell cycle arrest. Top/HDAC-IN-3 demonstrates a significant antitumor effect in NSCLC models, exhibiting a tumor growth inhibition (TGI = 77.5%, 100 mg/kg) superior to that of the HDAC inhibitor SAHA and the combination of SAHA with the topoisomerase inhibitor Irinotecan.</p>Fórmula:C24H25N3O5Cor e Forma:SolidPeso molecular:435.47EGFR-IN-47
<p>EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.</p>Fórmula:C29H35N7Cor e Forma:SolidPeso molecular:481.6406:0 PE
CAS:<p>06:0 PE (PE(6:0/6:0)) is a water-soluble phospholipid characterized by its short acyl chains. It possesses notable antitumor activity and can inhibit tumor progression in the body. Additionally, it exhibits antiproliferative and pro-apoptotic properties, and serves as a precursor for phosphatidylcholine and phosphatidylethanolamine.</p>Fórmula:C17H34NO8PCor e Forma:SolidPeso molecular:411.43Pim-1 kinase inhibitor 10
CAS:<p>Pim-1 Kinase Inhibitor 10 (compound 13a) acts as both a competitive and non-competitive inhibitor of PIM-1/2 kinase, promoting cell apoptosis and displaying anticancer properties. Additionally, this compound triggers the activation of caspase 3/7 [1].</p>Fórmula:C21H13N3O3Cor e Forma:SolidPeso molecular:355.35Antitumor agent-58
<p>Antitumor agent-58 suppresses tumor growth, colony formation, cell migration, and induces mitochondrial dysfunction in MGC-803 cells.</p>Fórmula:C27H28F3N9SCor e Forma:SolidPeso molecular:567.63TNF-α-IN-14
CAS:<p>TNF-α-IN-14, a potent TNFα inhibitor, exhibits a selective inhibition profile with an IC50 of 1.1 µM and demonstrates antiinflammatory properties (WO2001072735A2; compound 12) [1].</p>Fórmula:C22H26O6Cor e Forma:SolidPeso molecular:386.44WYJ-2
CAS:<p>WYJ-2, a selective agonist for toll-like receptor 2/1 (TLR2/1), demonstrates an EC50 of 18.57 nM in HEK 293T cells transiently co-transfected with human TLR2 and TLR1. It induces pyroptosis and has shown anticancer activity against non-small cell lung cancer (NSCLC) [1].</p>Fórmula:C17H9F2N3O4Cor e Forma:SolidPeso molecular:357.27LSD1-IN-21
<p>LSD1-IN-21: potent LSD1 inhibitor, crosses blood-brain barrier, IC50 of 0.956 μM; lowers TNF-α, anti-cancer, anti-inflammatory.</p>Fórmula:C24H25N5O2SCor e Forma:SolidPeso molecular:447.55Anticancer agent 54
<p>Anticancer agent 54 blocks cell cycle in G0/G1, induces apoptosis, and fights cancer via DNA embedding and ROS.</p>Fórmula:C33H36N6Cor e Forma:SolidPeso molecular:516.68NSC308848
CAS:<p>NSC308848 is an effective apoptosis (cell death) inducer that operates in a Myc-dependent manner. It acts by inhibiting Myc transactivation and disrupting the DNA binding activity of Myc family proteins.</p>Fórmula:C18H21N3O2Cor e Forma:SolidPeso molecular:311.378Decarbamoylmitomycin C
CAS:<p>Decarbamoylmitomycin C, an analog of Mitomycin C (MC), functions as a DNA alkylating agent. It is capable of activating chromatin relaxation by the ataxia-telangiectasia and Rad3-related protein (ATR) in a p53-independent manner.</p>Fórmula:C14H17N3O4Cor e Forma:SolidPeso molecular:291.302Anticancer agent 64
CAS:<p>Anticancer agent 64 (5m) induces apoptosis, has IC50 2.4μM in CCRF-CEM, activates caspases, cleaves PARP, affects mitochondria.</p>Fórmula:C31H46N2O2SCor e Forma:SolidPeso molecular:510.77CDK-IN-9
<p>CDK-IN-9: A potent CDK inhibitor, gels to enhance CDK12/DDB1 binding, targets CDK2/E (IC50: 4 nM), induces apoptosis via dephosphorylation.</p>Fórmula:C21H24N8SCor e Forma:SolidPeso molecular:420.53CP-31398
CAS:<p>CP-31398 stabilizes the active conformation of p53 in cancer cells with either mutated or wild-type p53, enhancing its activity. Additionally, CP-31398 upregulates target genes of p53 such as p21WAF1/Cip1 and KILLER/DR5. This compound possesses tumor-suppressive properties.</p>Fórmula:C22H26N4OCor e Forma:SolidPeso molecular:362.47Antiproliferative agent-63
CAS:<p>Antiproliferative agent-63 (compound 4d) is a cyclic analog of cannabidiol that acts as an anticancer agent. It demonstrates favorable activity against breast and colorectal cancer. Moreover, this compound can arrest the cell cycle in the G1 phase and induce apoptosis through the mitochondrial pathway in breast cancer cell lines.</p>Fórmula:C27H41NO2Cor e Forma:SolidPeso molecular:411.62IMB5046
CAS:<p>IMB5046 is a microtubule inhibitor that induces apoptosis (cell death) by obstructing the G2/M phase of the cell cycle. It possesses antitumor properties.</p>Fórmula:C19H20N2O5SCor e Forma:SolidPeso molecular:388.438Silvestrol
CAS:<p>Silvestrol is a eukaryotic translation initiation factor 4A inhibitor. Silvestrol causes autophagy and caspase-mediated apoptosis.</p>Fórmula:C34H38O13Pureza:98%Cor e Forma:SolidPeso molecular:654.66TLBC
CAS:<p>TLBC, a borane-chalcone derivative, exhibits dose-dependent inhibitory effects across various glioma cell lines with IC50 values ranging from 5.5 to 25.5 μM. TLBC induces apoptosis independently of alterations in the tumor suppressor factor p53.</p>Fórmula:C15H12BIO3Cor e Forma:SolidPeso molecular:377.97XIAP degrader-1
<p>XIAP degrader-1 is a small primary amine molecule that promotes the degradation of X-linked apoptosis inhibitory protein (XIAP).</p>Fórmula:C34H45N5O4Cor e Forma:SolidPeso molecular:587.75Lepidozin G
<p>Lepidozin G blocks cancer growth (IC50=4.2-5.7μM) and triggers apoptosis in PC-3 cells via mitochondria.</p>Fórmula:C30H48O4Cor e Forma:SolidPeso molecular:472.7BRD-K56819078
CAS:<p>BRD-K56819078, a Bcl-2 inhibitor, significantly reduces the burden of senescent cells and the mRNA expression of aging-related genes in the kidneys. It exerts its anti-aging effects by inhibiting cell apoptosis (apoptosis).</p>Fórmula:C24H20FN3O4S2Cor e Forma:SolidPeso molecular:497.56NCAO
CAS:<p>N-ω-chloroacetyl-L-ornithine (NCAO) serves as a powerful reversible competitive inhibitor of ornithine decarboxylase (ODC), displaying cytotoxic and antiproliferative properties against various tumor cell lines, with EC50 values spanning from 1 to 50.6 µM. In vitro studies reveal that NCAO promotes Apoptosis and restricts tumor cell migration. Additionally, it demonstrates significant antitumor efficacy in a mouse model, targeting both solid and ascitic tumors using the myeloma (Ag8) cell line. NCAO holds promise in the development of antitumor agents.</p>Fórmula:C7H13ClN2O3Cor e Forma:SolidPeso molecular:208.64Bcl-2-IN-3
CAS:<p>Bcl-2-IN-3 (Compound 10) is an inhibitor of Bcl-2, utilized in cancer research.</p>Fórmula:C16H16N2O4Cor e Forma:SolidPeso molecular:300.31K20
<p>K20 selectively inhibits KRas G12C (IC50: 1.16 nM), shows anticancer activity in H358 cells (IC50: 0.78 μM), and induces apoptosis via Erk dephosphorylation.</p>Fórmula:C24H20Cl2F4N4O2Cor e Forma:SolidPeso molecular:543.34microRNA-21-IN-1
CAS:<p>microRNA-21-IN-1: microRNA inhibitor, curbs HeLa/HCT-116 growth (IC50: 5.5/2.8 μM), induces HeLa apoptosis, elevates PTEN/EGR1/SLIT2, for cancer research.</p>Fórmula:C30H37FN6O3Cor e Forma:SolidPeso molecular:548.65PD-1/PD-L1-IN-16
<p>PD-1/PD-L1-IN-16 is a potent inhibitor of PD-1/PD-L1 (IC50: 53.2 nM) and has shown research potential for tumour immunotherapy.</p>Fórmula:C34H30N4O4Cor e Forma:SolidPeso molecular:558.63Tofacitinib Prodrug-1
<p>Tofacitinib Prodrug-1: an oral prodrug reducing Tofacitinib's side effects, treats ulcerative colitis in mice effectively with low toxicity.</p>Fórmula:C36H39ClN10O7Cor e Forma:SolidPeso molecular:759.21Pan-Trk-IN-3
<p>Pan-Trk-IN-3: potent Trk inhibitor (IC50: 2-26 nM), effective against drug-resistant mutants, induces apoptosis, anti-tumor effects.</p>Fórmula:C29H31ClN8O3Cor e Forma:SolidPeso molecular:575.06PD-L1/VISTA-IN-1
CAS:<p>PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual inhibitor targeting PD-L1 and VISTA. It effectively hinders the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), leading to the reactivation of T cells. Additionally, PD-L1/VISTA-IN-1 exhibits antitumor activity.</p>Fórmula:C22H24N4O4Cor e Forma:SolidPeso molecular:408.45Top/HDAC-IN-2
<p>Top/HDAC-IN-2 (45b) is a dual inhibitor of Top and HDAC that induces apoptosis and exhibits significant anti-tumour effects.</p>Fórmula:C30H32N8O4Cor e Forma:SolidPeso molecular:568.63TFCP2L1-IN-1
CAS:<p>TFCP2L1-IN-1 is a TFCP2L1 transcription factor inhibitor that regulates cell proliferation and promotes antitumor effect of Sorafenib by STAT3/NANOG pathway.</p>Fórmula:C15H13BrN2OSPureza:98.86%Cor e Forma:SolidPeso molecular:349.25Sabialimon P
CAS:<p>Sabialimon P (compound 16), with an IC50 of 18.12 μM, functions as a NO release inhibitor and exhibits anti-inflammatory properties. It effectively diminishes the secretion of TNF-α, iNOS, IL-6, and NF-κB, and suppresses the expression of COX-2 and NF-κB/p65 in LPS-induced RAW264.7 cells.</p>Fórmula:C31H50O4Cor e Forma:SolidPeso molecular:486.73Anticancer agent 68
CAS:<p>Compound 12, an anticancer agent, halts G2/M phase, triggers cell death, and activates p53 & PTEN for tumor suppression.</p>Fórmula:C20H18ClNO5Cor e Forma:SolidPeso molecular:387.81RMS5
CAS:<p>RMS5: hambanine analogue, inhibits P-gp, anti-cancer with cytotoxic, anti-proliferative effects, reduces Bcl-2 proteins, cleaves PARP.</p>Fórmula:C35H38N2O5SCor e Forma:SolidPeso molecular:598.75MI-888 TFA
CAS:<p>MI-888 (TFA) is an orally active inhibitor of the MDM2-p53 interaction with a Ki of 0.44 nM. It can induce rapid, complete, and durable tumor regression in xenograft mouse models.</p>Fórmula:C30H33Cl2F4N3O5Cor e Forma:SolidPeso molecular:662.5PIM1-IN-3
<p>PIM1-IN-3 (HL8) selectively blocks PIM1, induces Colo320 cell apoptosis, and may be researched for cancer.</p>Fórmula:C27H25BrN6OCor e Forma:SolidPeso molecular:529.43JAK-2/3-IN-3
<p>JAK-2-/3-IN-3 (ST4j) is a potent JAK2/3 inhibitor for leukemia research, with IC50s: JAK2, 13 nM; JAK3, 14.86 nM; induces apoptosis.</p>Fórmula:C13H10Cl2N4O2Cor e Forma:SolidPeso molecular:325.15AQX-435
CAS:<p>AQX-435 activates SHIP1, inhibits PI3K in BCR signaling, induces apoptosis in B cells, and slows lymphoma growth.</p>Fórmula:C27H34N2O4Cor e Forma:SolidPeso molecular:450.57MRK003
CAS:<p>MRK003, a γ-secretase inhibitor, induces apoptosis, halts cell growth in myeloma/NHL, and affects notch signaling and PI3K/Akt pathway.</p>Fórmula:C25H31F6N3O2SCor e Forma:SolidPeso molecular:551.59XPO1-IN-1
<p>XPO1-IN-1: an oral MM.1S cell inhibitor (IC50: 24 nM), induces apoptosis, stable metabolism, good pharmacokinetics.</p>Fórmula:C20H15F6N5O3SCor e Forma:SolidPeso molecular:519.42HDAC-IN-9
<p>HDAC-IN-9, a dual tubulin/HDAC inhibitor, impedes A549 cell invasion/migration and shows strong anti-tumor/angiogenic effects.</p>Fórmula:C33H38N2O4Cor e Forma:SolidPeso molecular:526.67pan-KRAS-IN-5
CAS:<p>Pan-KRAS-IN-5 (compound 15a) is a pan-KRAS translation inhibitor targeting 5′-UTR RNA G-quadruplexes (rG4s). It induces cell cycle arrest and promotes apoptosis in KRAS-driven cancer cells [1].</p>Fórmula:C31H36FIN4O2Cor e Forma:SolidPeso molecular:642.55Antitumor agent-72
CAS:<p>Antitumor agent-72 (compound 6w) is a potent anticancer agent that exhibits its anticancer activity by inducing apoptosis via caspase-3 activation and PARP</p>Fórmula:C25H20ClNO6Cor e Forma:SolidPeso molecular:465.88BRD1991
CAS:<p>BRD1991 is a chemical compound that specifically disrupts the interaction between Beclin 1 and Bcl-2, thereby inducing autophagy.</p>Fórmula:C33H35Cl2N3O4Cor e Forma:SolidPeso molecular:608.55FLT3/TrKA-IN-1
<p>FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.</p>Fórmula:C28H30N4O2Cor e Forma:SolidPeso molecular:454.56Tubulin inhibitor 43
CAS:<p>Tubulin inhibitor 43 exhibits significant antitumor activity by impeding the proliferation and growth of cancer cells through the inhibition of β-microtubulin activity, ultimately inducing apoptosis [1].</p>Fórmula:C20H21NO6Cor e Forma:SolidPeso molecular:371.38Ran-IN-1
CAS:Ran-IN-1 (Compound M36) is an orally active and selective inhibitor of Ran GTPase. It binds allosterically with high specificity to the switch II pocket of GDP-bound Ran (RanGDP), stabilizing its inactive state and reducing the formation of active Ran-GTP. Ran-IN-1 induces apoptosis in epithelial ovarian cancer (EOC) cells and inhibits DNA repair pathways such as homologous recombination (HR) and non-homologous end joining (NHEJ). This compound shows potential for research in epithelial ovarian cancer, particularly in high-grade serous carcinoma.Fórmula:C27H26F3NO4SCor e Forma:SolidPeso molecular:517.56GLUT-1-IN-4
CAS:<p>GLUT-1-IN-4 (Compound 13) is an inhibitor of the GLUT-1 glucose transporter that depends on the p53 protein. It suppresses the proliferation of various cancer cells at submicromolar IC50 levels. Additionally, GLUT-1-IN-4 can halt the cell cycle, induce oxidative stress, and promote apoptosis (cell death).</p>Fórmula:C15H10N2O3Cor e Forma:SolidPeso molecular:266.251ADH-6
CAS:<p>ADH-6, a tripyridylamide, disrupts mutant p53 aggregates in cancer cells, reviving its function and inducing apoptosis.</p>Fórmula:C29H36N8O9Cor e Forma:SolidPeso molecular:640.64PD-L1/HDAC6-IN-1
CAS:<p>PD-L1/HDAC6-IN-1 (Compound HP29) is an inhibitor targeting both PD-L1 and HDAC6, effectively disrupting the PD-L1/PD-1 interaction and inhibiting HDAC6 activity, with IC50 values of 26.8 nM and 69 nM, respectively. This compound enhances the cytotoxicity of Jurkat T cells against HepG2 cells, exhibiting an IC50 of 3.4 μM. In rats, PD-L1/HDAC6-IN-1 demonstrates favorable pharmacokinetics, showing a drug exposure level of 871.62 ng·h/mL, and displays antitumor activity in a B16-F10 xenograft mouse model.</p>Fórmula:C27H33N3O3Cor e Forma:SolidPeso molecular:447.569Flonoltinib sulfate
CAS:<p>Flonoltinib maleate is an orally active dual inhibitor of JAK2/FLT3, with IC50 values of 0.7 nM for JAK2, 4 nM for FLT3, 26 nM for JAK1, and 39 nM for JAK3. It exhibits anticancer properties.</p>Fórmula:C25H36FN7O5SCor e Forma:SolidPeso molecular:565.661TZEP7
CAS:<p>TZEP7 functions as an EGFR kinase inhibitor in cancer cells. It exhibits cytotoxicity and induces apoptosis within these cells. TZEP7 downregulates the anti-apoptotic protein Bcl-2, upregulates the pro-apoptotic protein Bax, and increases caspase levels. This compound holds potential for research in anticancer drug development.</p>Fórmula:C27H19ClFNSCor e Forma:SolidPeso molecular:443.963HL001
CAS:<p>HL001 is an orally active small molecule inhibitor of cyclophilin A (CypA) and a receptor antagonist of lysophosphatidic acid 1 (LPA1). It induces cell cycle arrest and apoptosis in tumor cells via p53. By downregulating G3BP1, HL001 promotes reactive oxygen species production and DNA damage to stabilize p53. It disrupts the interaction between MDM2 and p53-72R in a CypA-dependent manner. HL001 exhibits antitumor activity and can also be used in research on pulmonary fibrosis.</p>Fórmula:C21H16N2O4Cor e Forma:SolidPeso molecular:360.363CDK2-IN-9
<p>CDK2-IN-9: potent CDK2 inhibitor (IC50: 0.63 μM), anti-proliferative, arrests S/G2M cell cycle, induces apoptosis, promising for melanoma study.</p>Fórmula:C21H16ClN3O4SCor e Forma:SolidPeso molecular:441.89mTOR/HDAC6-IN-1
<p>mTOR/HDAC6-IN-1 inhibits HDAC6 (IC50: 56 nM) & mTOR (IC50: 133.7 nM), may treat TNBC by inducing autophagy and apoptosis.</p>Fórmula:C20H20ClN5O2Cor e Forma:SolidPeso molecular:397.86PI3K/AKT-IN-1
CAS:<p>PI3K/AKT-IN-1 is a dual inhibitor of PI3K and AKT with anti-cancer activity, inhibiting the PI3K/AKT pathway and inducing caspase 3-dependent apoptosis.</p>Fórmula:C23H23N5O4SPureza:99.84%Cor e Forma:SoildPeso molecular:465.53SphK1-IN-2
<p>SphK1-IN-2: SphK1 inhibitor, IC50: 19.81 nM; less effective on SphK2. Induces apoptosis, hinders cancer cell growth.</p>Fórmula:C27H30BrNO4SCor e Forma:SolidPeso molecular:544.5Tubulin inhibitor 17
<p>Compound 3b inhibits tubulin polymerization, IC50 12.38 µM, with anticancer properties and promotes cell apoptosis.</p>Fórmula:C17H16N2OCor e Forma:SolidPeso molecular:264.32Antitumor agent-77
<p>Antitumor agent-77 suppresses cancer cell growth, migration, induces apoptosis, and hinders EMT.</p>Fórmula:C7H11F3N2O5PtCor e Forma:SolidPeso molecular:455.25MTX-216
CAS:<p>MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.</p>Fórmula:C22H14Cl2FN5O2SCor e Forma:SolidPeso molecular:502.348MTDH-SND1 blocker 2
CAS:<p>MTDH-SND1 blocker 2 (compound C19) is an effective MTDH-SND1 inhibitor with an IC50 value of 487 nM. It binds to the SND1 protein with a Kd of 279 nM and can degrade the SND1 protein. Additionally, MTDH-SND1 blocker 2 exhibits antiproliferative activity and induces apoptosis, showing potential for breast cancer research.</p>Fórmula:C18H12FN3O2SCor e Forma:SolidPeso molecular:353.37GPD-1116
CAS:<p>GPD-1116 is an orally active inhibitor of phosphodiesterase (PDE)4 and PDE1. The compound effectively reduces smoke-induced apoptosis in lung cells. Additionally, GPD-1116 has shown efficacy in various animal disease models, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma, and pulmonary arterial hypertension.</p>Fórmula:C22H16N4OCor e Forma:SolidPeso molecular:352.39PROTAC FKBP Degrader-3
CAS:<p>PROTAC FKBP Degrader-3, with FKBP and VHL binding groups linked, is a potent FKBP degrader.</p>Fórmula:C68H90N6O17SPureza:98%Cor e Forma:SolidPeso molecular:1295.54AZD0424
CAS:<p>AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.</p>Fórmula:C25H29ClN6O5Pureza:98%Cor e Forma:SolidPeso molecular:528.99CB-184
CAS:<p>CB-184 is a selective ligand for sigma-2 (σ2) receptors, with Ki values of 7436 nM for sigma-1 (σ1) and 13.4 nM for sigma-2 (σ2), and it promotes apoptosis with antitumor activity.</p>Fórmula:C22H21Cl2NO2Cor e Forma:SolidPeso molecular:402.31SMO-IN-5
<p>SMO-IN-5 (Compound 25(B31)) is an effective inhibitor of smoothened (SMO), which suppresses the Hedgehog (Hh) signaling pathway. This compound inhibits cellular proliferation and induces apoptosis, demonstrating antitumor activity.</p>Fórmula:C25H24N6OCor e Forma:SolidPeso molecular:424.5PAK4-IN-5
<p>PAK4-IN-5 (Compound 12i) is a potent inhibitor of PAK4 (IC50: PAK4 at 7.68 nM, PAK1 at 1872.01 nM) that forms stable interactions with the PAK4 enzyme. This compound effectively inhibits the proliferation and migration potential of MDA-MB-231 cells by hindering the phosphorylation of PAK4 and LIMK1. Additionally, PAK4-IN-5 arrests the cell cycle in the G0/G1 phase, induces apoptosis, and prompts the production of reactive oxygen species. The LD50 in mice is greater than 500 mg/kg (oral).</p>Fórmula:C31H28ClN5OCor e Forma:SolidPeso molecular:522.04[D-Leu-4]-OB3
CAS:[D-Leu-4]-OB3 suppresses the expression of genes associated with inflammation, proliferation, and metastasis, as well as the expression of PD-L1.Fórmula:C29H50N8O12SCor e Forma:SolidPeso molecular:734.82p53 Activator 14
CAS:<p>p53 Activator 14 (Compound 7A) is a derivative of Neratinib that can induce DNA damage and activate p53, thereby inhibiting the proliferation of various cancer cells, with an IC50 of 7.21 μM for HCT116 cells. This compound hinders adhesion, migration, and invasion of HCT116 cells, disrupts the cell cycle, and triggers apoptosis. In addition, p53 Activator 14 exhibits anti-tumor properties and inhibits angiogenesis in the chick embryo chorioallantoic membrane (CAM) model.</p>Fórmula:C28H29ClN4O3Cor e Forma:SolidPeso molecular:505.008Zotatifin
CAS:<p>Zotatifin (eFT226) is a selective eIF4A inhibitor with antiviral and antitumor properties, inhibiting Sox4 translation and inducing apoptosis.</p>Fórmula:C28H29N3O5Pureza:98.85%Cor e Forma:SolidPeso molecular:487.55PF-07328948
CAS:<p>PF-07328948 is a branched-chain keto-acid dehydrogenase kinase (BDK) inhibitor, useful for studying CVD metabolic disorders.</p>Fórmula:C16H8F4O3SPureza:98.42%Cor e Forma:SolidPeso molecular:356.29Milademetan
CAS:<p>Milademetan (DS-3032), an MDM2 inhibitor, exhibits antitumor activity, induces G1 cell cycle arrest and apoptosis, and can be used to study solid tumors.</p>Fórmula:C30H34Cl2FN5O4Pureza:>99.99%Cor e Forma:SolidPeso molecular:618.53Tuvusertib
CAS:<p>Tuvusertib (M1774), an oral ATR inhibitor (Ki<1µM), selectively blocks CHK1 phosphorylation, disrupts DNA repair, and induces tumor cell apoptosis.</p>Fórmula:C16H12F2N8OPureza:98.44% - 99.66%Cor e Forma:SolidPeso molecular:370.32Lometrexol
CAS:<p>Lometrexol (LY 264618) is an antifolate that inhibits GARFT, blocks purine synthesis, induces apoptosis, and has anticancer properties.</p>Fórmula:C21H25N5O6Pureza:97.76% - 99.56%Cor e Forma:SolidPeso molecular:443.45HC-5404
CAS:<p>HC-5404 is a potent and selective PERK inhibitor, blocking the activation of the PERK pathway, anti-tumor effects, advanced solid tumors and renal cell Cancer.</p>Fórmula:C24H24F2N4O3Pureza:99.33%Cor e Forma:SolidPeso molecular:454.47Vatalanib hydrochloride
CAS:<p>Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.</p>Fórmula:C20H16Cl2N4Pureza:99.7%Cor e Forma:SolidPeso molecular:383.27UH15-38
CAS:<p>UH15-38 is a potent and selective RIPK3 inhibitor that blocks necroptosis in alveolar epithelial cells triggered by IAV, useful for studying lung inflammation.</p>Fórmula:C26H27N5O2Pureza:99.85%Cor e Forma:SolidPeso molecular:441.53BCL6-IN-3
CAS:<p>BCL6-IN-3: potent BCL6 inhibitor, 70 nM GI50 in SU-DHL4, affects cell functions, antitumor.</p>Fórmula:C24H31ClF2N6O2Pureza:98.17%Cor e Forma:SolidPeso molecular:508.99SY-5609
CAS:<p>SY-5609 (CDK7-IN-3) is a selective non-covalent CDK7 inhibitor, with weak inhibitory activity against CDK2, CDK9 and CDK12.Cost-effective and quality-assured.</p>Fórmula:C23H26F3N6OPPureza:99.34% - >99.99%Cor e Forma:SolidPeso molecular:490.46JAK2-IN-7
CAS:<p>JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.</p>Fórmula:C26H33N7OPureza:99.54%Cor e Forma:SolidPeso molecular:459.59Gemcitabine elaidate hydrochloride
CAS:<p>CP-4126, a lipophilic pro-drug of Gemcitabine, converts to active form by esterases, allowing oral administration with dose-dependent effects.</p>Fórmula:C27H44ClF2N3O5Pureza:98.50% - 99.6%Cor e Forma:SolidPeso molecular:564.11FX-11
CAS:<p>FX-11: potent LDHA inhibitor (Ki 8 μM), activates PKM2, reduces ATP, induces oxidative stress/ROS, cell death, shows antitumor effects.</p>Fórmula:C22H22O4Pureza:98.95%Cor e Forma:SolidPeso molecular:350.41AP1867-3-(aminoethoxy)
CAS:<p>AP1867-3-(aminoethoxy) is a synthetic ligand for FKBP and can be used in the synthesis of PROTAC FKBP12 F36V degrader.</p>Fórmula:C38H50N2O9Cor e Forma:SolidPeso molecular:678.81(R)-Verapamil hydrochloride
CAS:<p>(R)-Verapamil hydrochloride ((R)-(+)-Verapamil hydrochloride) is an inhibitor of P-Glycoprotein.</p>Fórmula:C27H39ClN2O4Cor e Forma:SolidPeso molecular:491.06OBAA
CAS:<p>OBAA is a potent inhibitor of phospholipase A2 (PLA2) with an IC 50 of 70 nM. OBAA blocks Melittin-induced Ca 2+ influx in Trypanosoma brucei with an IC 50 of 0.4 μM [1] [2] [3].</p>Fórmula:C28H44O3Pureza:98%Cor e Forma:SolidPeso molecular:428.65β-Zearalanol
CAS:Beta-Zearalenol, a derivative of zearalenone (ZEA) capable of conjugating with glucuronic acid[2], is a mycotoxin produced by Fusarium spp. It induces apoptosis and oxidative stress in mammalian reproductive cells[1].Fórmula:C18H26O5Cor e Forma:SolidPeso molecular:322.4PIM-447 dihydrochloride
CAS:<p>PIM-447 dihydrochloride is an orally available and selective inhibitor of pan-PIM kinase(Ki values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively).</p>Fórmula:C24H25Cl2F3N4OPureza:98%Cor e Forma:SolidPeso molecular:513.38WEHI-539 hydrochloride
CAS:<p>WEHI-539 hydrochloride is a selective Bcl-XL inhibitor with an IC50 of 1.1 nM.</p>Fórmula:C31H30ClN5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:620.18Actinonin
CAS:<p>Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces and a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. It also induces apoptosis and inhibits aminopeptidase M, aminopeptidase N, and leucine aminopeptidase, as well as MMP-1, MMP-3, MMP-8, MMP-9, and meprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin exhibits antiproliferative and antitumor activities [1][2][3][4][5].</p>Fórmula:C19H35N3O5Cor e Forma:SolidPeso molecular:385.55-Amino-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide
CAS:Fórmula:C9H14N4O5Pureza:95%Cor e Forma:SolidPeso molecular:258.2313Platinum, diammine[1,1-cyclobutanedi(carboxylato-kO)(2-)]-, (SP-4-2)-
CAS:Fórmula:C6H10N2O4PtPureza:98%Cor e Forma:SolidPeso molecular:369.2326Ref: IN-DA00I84B
Produto descontinuadoThalidomide-O-C5-NH2 hydrochloride
CAS:<p>Thalidomide-O-C5-NH2 hydrochloride is a synthetic compound consisting of a ligand-linker conjugate with E3 ligase activity. It combines a cereblon ligand based on Thalidomide and a linker commonly utilized in PROTAC technology.</p>Fórmula:C18H22ClN3O5Cor e Forma:SolidPeso molecular:395.84Prostaglandin A2
CAS:<p>PGA2 is a naturally occurring prostaglandin in gorgonian corals where it may function in self defense. It is generally not present in mammals. PGA2 has low biological potency in most bioassays, but it does show some antiviral/antitumor activity.[1] At a 25 uM concentration, PGA2 blocks the cell cycle progression of NIH 3T3 cells at the G1 and G2/M phase .[2] It has also been shown to act as a vasodilator with natriuretic properties.[3]</p>Fórmula:C20H30O4Cor e Forma:SolidPeso molecular:334.45Ciprofloxacin lactate
CAS:<p>Ciprofloxacin lactate is a useful organic compound for research related to life sciences. The catalog number is T66299 and the CAS number is 97867-33-9.</p>Fórmula:C20H24FN3O6Cor e Forma:SolidPeso molecular:421.43Thalidomide-5-COOH
CAS:<p>Thalidomide-5-COOH is a useful organic compound for research related to life sciences. The catalog number is T64600 and the CAS number is 1216805-11-6.</p>Fórmula:C14H10N2O6Cor e Forma:SolidPeso molecular:302.242Ac-IETD-CHO TFA
<p>Ac-IETD-CHO TFA is a granzyme B and caspase-8 inhibitor that inhibits caspase8 activity by blocking caspase3 precursor cleavage.Ac-IETD-CHO TFA inhibits Fas-mediated apoptosis.</p>Fórmula:C23H35F3N4O12Cor e Forma:SoildPeso molecular:616.54SCH79797
CAS:<p>SCH79797 is a potent and specific protease-activated receptor 1 (PAR1) antagonistwith antimicrobial, anticancer, anti-inflammatory, and neuroprotective effects.</p>Fórmula:C23H25N5Pureza:99.80%Cor e Forma:SolidPeso molecular:371.48A-192621
CAS:<p>A-192621 is a potent, nonpeptide, orally active, and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. A-192621 promotes apoptosis in PASMCs and elevates both arterial blood pressure and plasma ET-1 levels[1][2][3]. Its selectivity is 636-fold higher for ETB than ETA (IC50 of 4280 nM and Ki of 5600 nM).</p>Fórmula:C33H38N2O6Pureza:98%Cor e Forma:SolidPeso molecular:558.66MI-773
CAS:<p>MI-773 is a potent inhibitor of the MDM2-p53 protein interaction (PPI) with a high affinity for MDM2 and a Kd value of 8.2 nM. MI-773 exhibits antitumour effects.</p>Fórmula:C29H34Cl2FN3O3Cor e Forma:SolidPeso molecular:562.5XMU-MP-3
CAS:<p>XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.</p>Fórmula:C27H27F3N8OCor e Forma:SolidPeso molecular:536.563ENMD-2076 tartrate
CAS:<p>ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.</p>Fórmula:C25H31N7O6Cor e Forma:SolidPeso molecular:525.56RRD-251
CAS:<p>RRD-251 is an Rb-Raf-1 interaction inhibitor that induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine[1].</p>Fórmula:C8H9Cl3N2SCor e Forma:SolidPeso molecular:271.59Swainsonine
CAS:<p>Swainsonine (Tridolgosir) is an alkaloid isolated from Astragalus membranaceus and is a potent and reversible inhibitor of alpha-mannosidase. swainsonine has antitumour activity and induces apoptosis and cell cycle arrest in the G2/M phase.</p>Fórmula:C8H15NO3Pureza:98%Cor e Forma:Lyophilized PowderPeso molecular:173.21Ingenol 3,20-dibenzoate
CAS:<p>Ingenol 3,20-dibenzoate is a powerful activator of protein kinase C (PKC) isoforms that effectively induces the translocation of nPKC-delta, -epsilon, and -theta, as well as PKC-mu, from the cytosolic fraction to the particulate fraction. Through de novo synthesis of macromolecules, it triggers apoptosis with characteristic morphology. Moreover, Ingenol 3,20-dibenzoate enhances IFN-γ production and degranulation in NK cells, particularly when stimulated by NSCLC cells[1][2].</p>Fórmula:C34H36O7Cor e Forma:SolidPeso molecular:556.65Vatiquinone
CAS:<p>Vatiquinone, also known as EPI 743, is an orally bioavailable para-benzoquinone being developed for inherited mitochondrial diseases. The mechanism of action of EPI-743 involves augmenting the synthesis of glutathione, optimizing metabolic control, enhanc</p>Fórmula:C29H44O3Cor e Forma:SolidPeso molecular:440.66Thalidomide-O-amido-C4-NH2 hydrochloride
CAS:<p>Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand derived from Thalidomide with a linker and is commonly used in the synthesis of PROTACs[1].</p>Fórmula:C19H23ClN4O6Pureza:98%Cor e Forma:SolidPeso molecular:438.86Imifoplatin
CAS:<p>Imifoplatin (PT-112) is a platinum compound with antitumor activity and may be used to study prostate cancer and immune system disorders.</p>Fórmula:C6H16N2O7P2PtPureza:≥95.0%Cor e Forma:SolidPeso molecular:485.23Yatein
CAS:<p>Yatein inhibits herpes simplex virus type 1 replication by interruption the immediate-early gene expression. Yatein is a lignan isolated from A. chilensis. It also has antiproliferative activity.</p>Fórmula:C22H24O7Pureza:98%Cor e Forma:SolidPeso molecular:400.42Carubicin hydrochloride
CAS:<p>Carubicin HCl is an anthracycline antineoplastic antibiotic. Through intercalates into DNA and interacts with topoisomerase II, Carubicin inhibits DNA replication and repair and RNA and protein synthesis.</p>Fórmula:C26H28ClNO10Cor e Forma:SolidPeso molecular:549.95Thalidomide-O-C6-COOH
CAS:<p>Thalidomide-O-C6-COOH is a synthetic conjugate that combines a Thalidomide-derived cereblon ligand with a PROTAC technology linker (E3 ligase ligand-linker).</p>Fórmula:C20H22N2O7Cor e Forma:SolidPeso molecular:402.403Mcl-1 inhibitor 6
CAS:<p>Mcl-1 inhibitor 6 binds Mcl-1 with KD 0.23 nM and Ki 0.02 μM, shows strong selectivity over Bcl-2 family, and demonstrates antitumor efficacy.</p>Fórmula:C26H28ClNO6SCor e Forma:SolidPeso molecular:518.02DB818
CAS:<p>DB818 is a synthetic Homeobox A9 (HOXA9) inhibitor and can be used for research on the treatment of acute myeloid leukaemia associated with HOXA9 overexpression.</p>Fórmula:C19H16N6SPureza:98%Cor e Forma:SolidPeso molecular:360.44CTB
CAS:<p>CTB (Cholera Toxin B subunit) is an activator of p300 histone acetyltransferase and induces apoptosis in MCF-7 cells.</p>Fórmula:C16H13ClF3NO2Pureza:99.82%Cor e Forma:SolidPeso molecular:343.73anti-TNBC agent-2
CAS:<p>Anti-TNBC agent-2 (3j), a purine derivative, acts as an anti-triple negative breast cancer (TNBC) therapeutic.</p>Fórmula:C28H37ClFN7OPureza:98%Cor e Forma:SolidPeso molecular:542.09Ref: TM-T79699
Produto descontinuadoCyy-272
CAS:<p>Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25, 1.07, and 1.24 μM against JNK1, JNK2, and JNK3, respectively. It exerts anti-inflammatory effects by inhibiting the phosphorylation of JNK, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS). Moreover, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissues caused by high lipid concentrations, further mitigating resultant cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 is utilized in the study of obesity-related myocarditis.</p>Fórmula:C23H23F2N7Cor e Forma:SolidPeso molecular:435.47Ref: TM-T200453
Produto descontinuadoIHMT-MST1-39
CAS:<p>IHMT-MST1-39 is an orally effective MST kinase inhibitor with IC50 values of 42 nM for MST1 and 109 nM for MST2. It activates the AMPK signaling pathway in hepatocytes and inhibits apoptosis in pancreatic β cells. Additionally, IHMT-MST1-39 improves type 1 diabetes in mice induced by Streptozotocin.</p>Fórmula:C20H18F2N6O3SCor e Forma:SolidPeso molecular:460.46Ref: TM-T200512
Produto descontinuadoCHMFL-48
CAS:<p>CHMFL-48, an orally active inhibitor of BCR-ABL kinase, demonstrates efficacy against both the wild-type (wt) and various imatinib-resistant mutants. It exhibits potent inhibitory activity, with IC 50 values of 1 nM for the ABL wild-type and 0.8 nM for the ABL T315I mutant. CHMFL-48 operates by inhibiting the autophosphorylation of both wild-type and mutant BCR-ABL, affecting downstream signaling mediators including STAT5 and CRKL. This disruption leads to cell cycle arrest and triggers apoptosis. Given its properties, CHMFL-48 is a promising candidate for research on chronic myeloid leukemia (CML).</p>Fórmula:C31H30F3N7OCor e Forma:SolidPeso molecular:573.61SMIP34
CAS:<p>SMIP34 is an inhibitor of PELP1 that demonstrates the capability to reduce cell viability and colony formation. Additionally, SMIP34 induces cell apoptosis (apoptosis) and causes cell cycle arrest in the S phase. It reduces the expression of PELP1 and exhibits anti-tumor activity. SMIP34 also has potential for research in triple-negative breast cancer (TNBC).</p>Fórmula:C20H15ClFN5O2SCor e Forma:LiquidPeso molecular:443.88Taltobulin
CAS:<p>Taltobulin (HTI-286) is a synthetic analog of the tripeptide cysteine, a microtubule protein inhibitor that inhibits liver tumor cell proliferation in vitro and tumor growth in vivo.Taltobulin is cytotoxic, induces mitotic arrest and apoptosis, and may be used in the study of breast cancer and microtubule tissue-related diseases.</p>Fórmula:C27H43N3O4Pureza:99.86%Cor e Forma:SolidPeso molecular:473.65ZSQ836
CAS:<p>ZSQ836 is a dual covalent inhibitor of CDK12/CDK13 with oral bioactivity, displaying an EC50 value of 32 nM against CDK12. This compound can induce cell apoptosis (apoptosis) and demonstrates in vivo anticancer properties. ZSQ836 is applicable for research in ovarian cancer.</p>Fórmula:C27H28AsClN6OS2Cor e Forma:SolidPeso molecular:627.05Ref: TM-T200333
Produto descontinuadoDETD-35
CAS:<p>DETD-35 is a promising chemical compound in anti-melanoma therapy, functioning as an inhibitor of the MEK-ERK, Akt, and STAT3 signaling pathways. It enhances cancer cell apoptosis (Apoptosis) and diminishes resistance to Vemurafenib in cancer cells. The compound exhibits IC 50 values of 2.7, 6.0, 3.9, 3.1, and 2.5 μM against melanoma cell lines B16-F10, MeWo, SK-MEL-2, A2058c, and A375c, respectively. DETD-35 offers significant potential for advancing research in melanoma treatment strategies.</p>Fórmula:C27H24O6Cor e Forma:SolidPeso molecular:444.48
![[D-Leu-4]-OB3](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT72906.webp&w=3840&q=75)
![Platinum, diammine[1,1-cyclobutanedi(carboxylato-kO)(2-)]-, (SP-4-2)-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA00I84B.webp&w=3840&q=75)
